All In Biotech

Drug Trial Radar · NCT07877519

Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fibrillation

Efficacy and Safety of Local Anesthesia With Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Patients With Paroxysmal Atrial Fibrillation: A Prospective, Multicenter, Randomized, Controlled, Noninferiority Trial

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
China National Center for Cardiovascular DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Oct 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, multicenter, randomized, controlled, noninferiority trial will compare local anesthesia with conscious sedation and general anesthesia in patients undergoing pulsed field ablation for paroxysmal atrial fibrillation. A total of 390 participants aged 18 to 80 years will be randomly assigned in a 1:1 ratio to undergo pulsed field ablation under either local anesthesia with conscious sedation or general anesthesia. Both groups will receive pulmonary vein isolation using the same pulsed field ablation strategy. The primary outcome is recurrence of an electrocardiographically documented atrial tachyarrhythmia after an 8-week post-ablation blanking period. Recurrence is defined as atrial fibrillation, atrial flutter, or atrial tachycardia lasting at least 30 seconds through 12 months after ablation. The study will also compare the ability of each anesthesia strategy to support successful completion of the ablation procedure, anesthesia-related and ablation-related complications, procedural efficiency, patient-reported pain and anxiety, overall procedural experience, and direct medical costs.

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

  • Local Anesthesia With Conscious SedationProcedure

    Protocol-specified antitussive pretreatment is followed by local anesthesia, analgesia, and conscious sedation. Before femoral venous puncture, intravenous tropisetron hydrochloride 5 mg, dexamethasone 5 mg, lidocaine 100 mg over 10 minutes, fentanyl 50 micrograms, midazolam 2 mg, and atropine 1 mg are given. After transseptal puncture, fentanyl 50-100 micrograms is given intravenously, followed by 0.04 micrograms/kg/min infusion. Additional midazolam or fentanyl may be given according to vital signs and clinical tolerance. Conversion to general anesthesia is permitted for persistent severe coughing, pain, anxiety, or agitation interfering with catheter positioning or energy delivery; persistent respiratory depression or refractory hypoxemia; uncorrectable hemodynamic instability; or inability or unwillingness to tolerate the assigned strategy.

  • General AnesthesiaProcedure

    General anesthesia will be induced, maintained, and monitored by an anesthesiologist according to routine clinical practice at each participating center. Airway management, anesthetic medications, ventilation parameters, hemodynamic management, and post-anesthesia recovery will be documented.

  • VARIPULSE Pulsed Field Ablation SystemDevice

    All participants will undergo bilateral pulmonary vein isolation using the VARIPULSE pulsed field ablation catheter under CARTO 3 electroanatomic mapping guidance. Additional ablation of the left atrial posterior wall, superior vena cava, or other atrial substrate may be performed when clinically indicated. Bidirectional pulmonary vein isolation will be evaluated at the end of the procedure. Activated clotting time will be maintained at 350 seconds or longer during left atrial ablation.

  • Compound methoxyphenamine capsulesDrug

    Oral antitussive pretreatment with compound methoxyphenamine capsules (Asmeton) during the 24 hours before the procedure, as specified in the protocol.

  • SalbutamolDrug

    Nebulized pretreatment in combination with budesonide and lidocaine within 90 minutes before the procedure, as specified in the protocol for the local anesthesia with conscious sedation arm.

  • BudesonideDrug

    Nebulized pretreatment in combination with salbutamol and lidocaine within 90 minutes before the procedure, as specified in the protocol for the local anesthesia with conscious sedation arm.

  • LidocaineDrug

    Administered by nebulization with salbutamol and budesonide within 90 minutes before the procedure, and intravenously before femoral venous puncture, as specified in the protocol for the local anesthesia with conscious sedation arm.

  • FentanylDrug

    For the local anesthesia with conscious sedation arm: intravenous fentanyl 50 micrograms before femoral venous puncture, followed by 50 to 100 micrograms after transseptal puncture and a continuous intravenous infusion at 0.04 micrograms/kg/min. Additional doses may be administered according to vital signs, pain, and clinical tolerance, as specified in the protocol.

  • MidazolamDrug

    For the local anesthesia with conscious sedation arm: intravenous midazolam 2 mg before femoral venous puncture. Additional doses may be given according to vital signs and clinical response, as specified in the protocol.

  • Tropisetron hydrochlorideDrug

    Intravenous tropisetron hydrochloride 5 mg before femoral venous puncture as part of the protocol-specified premedication regimen for the local anesthesia with conscious sedation arm.

  • DexamethasoneDrug

    Intravenous dexamethasone 5 mg before femoral venous puncture as part of the protocol-specified premedication regimen for the local anesthesia with conscious sedation arm.

  • AtropineDrug

    Intravenous atropine 1 mg before femoral venous puncture as part of the protocol-specified premedication regimen for the local anesthesia with conscious sedation arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Recurrence of Atrial Tachyarrhythmia After the Blanking PeriodTime frame: From the end of the 8-week post-ablation blanking period through 12 months after the index ablation procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.